ClinicalTrials.gg
CompletedNCT06889779DORPHIUpdated Jul 22, 2026

Study Evaluating the Efficacy of Different Mixes of HMO-2FL + Humiome® Post LB on IBS Gastrointestinal Symptoms

An interventional study of MIX 1 and MIX 2 in IBS (Irritable Bowel Syndrome), sponsored by dsm-firmenich Switzerland AG. Completed at 12 sites in India. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-07-22.

Sponsored by dsm-firmenich Switzerland AG (part of dsm-firmenich) · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
353
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

A randomized, placebo-controlled, double-blind clinical study to evaluate the efficacy of two different mixes of HMO-2'-O-fucosyllactose (HMO-2FL) + Humiome® Post LB postbiotic (postbiotic-LB) on Gastrointestinal Symptoms in individuals with Irritable Bowel Syndrome (IBS)

Read the detailed description

This study is a randomized, placebo-controlled, double-blind clinical trial designed to assess the efficacy of two distinct formulations combining Human Milk Oligosaccharide 2'-O-fucosyllactose (HMO-2FL) with Humiome® Post LB postbiotic (postbiotic-LB) in alleviating gastrointestinal symptoms in individuals with Irritable Bowel Syndrome (IBS). Participants will be randomly assigned to receive either of the two active formulations or a placebo, ensuring unbiased comparisons. We aim to evaluate changes in gastrointestinal symptoms, including abdominal pain, bloating, and bowel movement patterns, using validated symptom scoring tools. We will assess the quality of life, gut health biomarkers, and safety profiles. The study employs a double-blind design, where neither participants nor investigators will know the treatment assignments, maintaining the study's integrity. By comparing the effects of different HMO-2FL and postbiotic-LB combinations, this trial aims to provide evidence-based insights into novel dietary supplement options for IBS management, contributing to the growing field of gut health and microbiome-targeted solutions.

02

Conditions studied

  • IBS (Irritable Bowel Syndrome)

Keywords

  • Dietary supplement IBS
03

In context

Irritable Bowel Syndrome

1,121 studies on the registry are indexed under Irritable Bowel Syndrome; 212 are open to participants now.

This study's enrollment of 353 is above the median of 70 across 900 interventional studies indexed under Irritable Bowel Syndrome.

Browse Irritable Bowel Syndrome studies →

Lead sponsor

dsm-firmenich Switzerland AG is the lead sponsor of 10 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  • Written and signed (will be obtained before any study-related Assessments).
  • Male or female aged ≥18 - 70 years at the time of consent.
  • Female individuals of (Females who are peri or , i.e., when there has been no or irregular menstruation for a minimum of 12 months prior to screening, are considered not to be of child-bearing potential.), who are not surgically sterilized, must have a negative pregnancy test at screening and be willing to practice one of the following appropriate methods until:

    • Sexual abstinence.
    • Oral contraceptives.
    • Trans-dermal patches or depot
    • injection of a progestogen drug (starting at least 4 weeks prior to product administration).
    • Double barrier method: condom or occlusive cap (diaphragm or cervical/vault caps) plus spermicidal agent.
    • Intrauterine device (IUD), intrauterine system (IUS), subdermal implant, or vaginal ring (placed at least 4 weeks prior to product administration/2 weeks prior screening).
    • Contraceptives must be effective before the randomization visit.
  • Individuals with plasma FBG (fasting blood glucose) (less than equal to 125 mg/dl).
  • Individuals with (Hb%) (more than equal to 10 g/dl).
  • Individuals with BP (blood pressure) (less than equal to 140/100 mm Hg)
  • Individuals with normal haematology as assessed by CBC (complete blood counts)
  • Individuals with TSH levels in between 0.4 mIU/L to 5.0 mIU/L
  • Individuals with and SGPT within 2 X the Upper normal limit () and serum
  • Individuals with creatinine within 1.5 X ULN
  • Rome-IV diagnostic criteria: Individuals with more than 25% of bowel movements with Bristol stool types 1, 2 or 6,7 and have had recurrent abdominal pain, on average, at least 1 day/week in the last 3 months. And the pain is associated with two or more of the following criteria:

    • Related to defecation
    • Associated with a change in frequency of stool
    • Associated with a change in form or appearance of stool as
    • assessed by Bristol stool types 1,2, 6 or 7.
    • Individuals meeting the above criteria for the last 3 months with
    • symptom onset at least 6 months before diagnosis
  • Individuals with Abdominal pain severity (more than equal to 6 on a 11-point scale) at screening and during placebo run-in period.
  • Individuals with IBS-SSS of at least 175 points at screening.
  • Individuals who are mentally stable as assessed by Perceived Stress Scale (PSS) less than equal to 26 (Low to Moderate stress).
  • Individuals who understand the nature and purpose of the study including the potential risks and side effects.
  • Individuals who are willing to complete all study procedures including study-related questionnaires and comply with study requirements.
  • Individuals who are capable of filling the app-based digital form/diary.

Exclusion Criteria:

  • Individuals with IBS-M.
  • Treatment with an drug within 30 days/5 half-lives of the drug (whichever longest) prior to screening visit.
  • Individuals with organic disease like infectious diseases, inflammatory diseases, metabolic disorders, neurological diseases, disorders, cancer etc. (to be ruled out by physician based on prior history and physical examination).
  • Individuals with a history of surgical resection of the stomach, small intestine or large intestine.
  • Individuals with a history of or complications from inflammatory bowel disease (Crohn's disease or ulcerative colitis), colitis and enteritis.
  • Individuals with a history of any diet-based intolerance (gluten or lactose intolerance).
  • Individuals with a history of drug or alcohol abuse within the past 6 months.
  • Individuals with severe depression or an anxiety disorder, which could potentially affect the efficacy evaluation (as determined by the qualified investigator).
  • Individuals with uncontrolled hypertension or on antihypertensive medications.
  • Individuals with serious cardiovascular diseases, respiratory diseases, renal diseases, hepatic diseases, gastrointestinal diseases (excluding IBS), blood diseases or neurological or psychiatric diseases.
  • Individuals who are pregnant, breastfeeding or planning on becoming pregnant throughout the course of the study.
  • Individuals with Type I or Type II diabetes mellitus.
  • Individuals with a history of or current diagnosis of any cancer diagnosed less than 5 years prior to screening. Individuals with cancer in full remission more than 5 years after diagnosis are acceptable.
  • Individuals who are immuno-compromised ( positive, on antirejection medication, rheumatoid arthritis and other autoimmune disorders).
  • Individuals with a history of abdominal surgery.
  • Individuals with diarrhoea of any other origin.
  • Individuals currently or in future planning to fast for more than 24 hours.
  • Individuals with an active eating disorder.
  • Individuals who have used an over-the-counter or prescription laxative medication or any other herbal agents affecting GI motility within 2 weeks prior to screening.
  • Individuals who have used pre/pro/post/synbiotic, Human Milk Oligosaccharides (HMOs), or fiber supplements (or probiotic/fiber enriched foods) or FODMAP diet or an antibiotic within 4 weeks prior to screening.
  • Individuals who have used IBS specific treatments within 4 weeks prior to screening.
  • Individuals who currently consume greater than 2 standard alcoholic drinks per day from past 3 months. ((One unit of alcohol is equal to 45 ml of hard liquor, 150 ml of wine or a pint of beer)
  • Smokers (in any number and any format)
  • Individuals with an allergy or sensitivity to the probiotic products.
  • Individuals who are cognitively impaired and/or who are unable to give an informed consent.
  • Individuals who have abnormal laboratory results or any other medical or psychological condition which, in the opinion of the qualified investigator, may adversely affect the Individuals' ability to complete the study or its measures or which may pose significant risk to the individual.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
353 participants (actual)

Study arms

  • Active comparator
    MIX 1

    Humiome® Post LB postbiotic 300 mg , Human Milk Oligosaccharides 2'-O-fucosyllactose 300 mg 1 capsule per day orally

    Dietary Supplement: MIX 1

  • Active comparator
    MIX 2

    Humiome® Post LB postbiotic 100 mg Human Milk Oligosaccharides 2'-O-fucosyllactose 500 mg 1 capsule per day orally

    Dietary Supplement: MIX 2

  • Placebo comparator
    Placebo

    Microcrystalline 1 capsule per day orally

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementMIX 1

    Humiome® Post LB postbiotic 300 mg , Human Milk Oligosaccharides 2'-Ofucosyllactose 300 mg 1 capsule per day Orally

  • Dietary supplementMIX 2

    Humiome® Post LB postbiotic 100 mg Human Milk Oligosaccharides 2'-O-fucosyllactose 500 mg 1 capsule per day Orally

  • Dietary supplementPlacebo

    Microcrystalline cellulose 1 capsule per day Orally

06

What researchers measure

Primary outcomes

  1. To assess the efficacy of 6 weeks of daily consumption of two different mixes of HMO 2'-O-fucosyllactose (HMO-2FL) + Humiome® Post LB postbiotic (postbiotic-LB) on IBS symptoms as assessed by IBS Symptom Severity Scale (IBS-SSS), when compared to placebo

    The IBS Severity Scoring System (IBS-SSS) will be used to assess symptom severity. Participants will rate their symptoms over the last 10 days on day 0 and day 42. The change in the average IBS severity score will be calculated and compared to the placebo group.

    Time frame: Day 0 & Day 42

Secondary outcomes

  1. To assess the efficacy of daily consumption of two different mixes of HMO 2'-O-fucosyllactose + Humiome® Post LB postbiotic on IBS symptoms as assessed by IBS Symptom Severity Scale , when compared to placebo in individuals

    The IBS Severity Scoring System (IBS-SSS) will be used to assess symptom severity. Participants will rate their symptoms over the last 10 days on day 0 and day 21. The change in the average IBS severity score will be calculated and compared to the placebo group.

    Time frame: Day 0, Day 21

  2. To assess the efficacy of 6 weeks of daily consumption of two different mixes of HMO 2'-O-fucosyllactose (HMO-2FL) + Humiome® Post LB postbiotic (postbiotic-LB); on IBS symptoms as assessed by IBS-SSS, when compared to baseline in individuals with IBS

    The IBS Severity Scoring System (IBS-SSS) will be used to assess symptom severity. Participants will rate their symptoms over the last 10 days on day 0 and day 42. The change in the average IBS severity score will be calculated and compared to baseline in individuals with IBS.

    Time frame: Day 0, Day 21 and Day 42

  3. To assess the efficacy of 6 weeks of daily consumption of two different mixes of HMO 2'-O-fucosyllactose (HMO-2FL) + Humiome® Post LB postbiotic (postbiotic-LB); on Abdominal Pain severity compared to baseline, each other and placebo in individuals with

    Decrease in Abdominal pain severity as assessed by APS-NRS (Abdominal pain severity - Numeric rating scale)

    Time frame: Day 0, Day 21 and Day 42

  4. To assess the efficacy of 6 weeks of daily consumption of two different mixes of HMO 2'-O-fucosyllactose + Humiome® Post LB postbiotic on participant by Stool consistency (Bristol Stool Form Scale types 3, 4 & 5)

    In gastroenterology, stool consistency is commonly measured using the Bristol Stool Form Scale (BSFS), which categorizes stool into seven types, from type 1 (hard lumps) to type 7 (watery diarrhea). It is a simple, cost-effective tool used as a marker for intestinal transit time and bowel function. In this study, stool consistency will be assessed using the BSFS.

    Time frame: Time Frame: Day 0, Day 21 and Day 42

  5. To assess the efficacy of 6 weeks of daily consumption of two different mixes of HMO 2'-O-fucosyllactose + Humiome® Post LB postbiotic on participant by Quality of Life score as assessed by IBS- QoL questionnaire

    The quality of life will be assessed using the IBS-QOL scale. The participants will be asked to score based on their symptoms in the last month at day 0, day 21, and day 42.

    Time frame: day 0, day 21, and day 42

  6. To assess the efficacy of 6 weeks of daily consumption of two different mixes of HMO 2'-O-fucosyllactose + Humiome® Post LB postbiotic on participant by decreased Abdominal bloating as assessed by Gastrointestinal Quality of Life

    The Gastrointestinal Quality of Life Index (GIQLI) is a validated 36-item tool for assessing health-related quality of life across five domains: core symptoms (10 items), physical (6 items), psychological (6 items), social (2 items), and disease-specific (8 items). Each item uses a 0-4 Likert scale, with higher scores indicating better quality of life. Total scores range from 0 to 144, where higher scores reflect improved quality of life.

    Time frame: day 0, day 21, and day 42

  7. To assess the efficacy on Increased percentage of responders to the treatment based on improvement on primary objective. The IBS-SSS is responsive to treatment; therefore, it has been used as a valid tool for performing responder analysis in IBS studies.

    The number of responders will be calculated separately for the two definitions given below in the present study: 1. 50 points change in IBS-SSS total score from baseline. 2. 95 points change in IBS-SSS total score from baseline.

    Time frame: day 0, day 21 and day 42

  8. To assess the efficacy of 6 weeks of daily consumption of two different mixes of HMO 2'-O-fucosyllactose (HMO-2FL) + Humiome® Post LB postbiotic (postbiotic-LB); on daily number of stool sample

    Will be assessed by Reduced Daily number of stools (stool frequency, assessed per IBS sub-type

    Time frame: Daily from start of the study to Week 6

  9. To assess the efficacy of 6 weeks of daily consumption of two different mixes of HMO 2'-O-fucosyllactose (HMO-2FL) + Humiome® Post LB postbiotic (postbiotic-LB); on Absolute difference in rescue medication consumption in active and placebo groups.

    Reduced Absolute difference in rescue medication consumption

    Time frame: Daily from start of the study to Week 6

  10. To assess the efficacy of 6 weeks of daily consumption of two different mixes of HMO 2'-O-fucosyllactose (HMO-2FL) + Humiome® Post LB postbiotic (postbiotic-LB); on Subjective global assessment of IP tolerability by participants.

    Will be measured by subjective global assessment of IP tolerability by participants

    Time frame: Daily from start of the study to Week 6

  11. To assess the efficacy of 6 weeks of daily consumption of two different mixes of HMO 2'-O-fucosyllactose (HMO-2FL) + Humiome® Post LB postbiotic (postbiotic-LB); on IBS-related mental stress relief

    Will be measured by Perceived stress scale (PSS)

    Time frame: Day 0 and day 42

  12. To assess the efficacy of 6 weeks of daily consumption of two different mixes of HMO 2'-O-fucosyllactose (HMO-2FL) + Humiome® Post LB on Gut Permeability assessment (Lactulose to Mannitol ratio test) [to be conducted in 30 participants in each arm]

    Will be measured by measuring the decrease in Lactulose Mannitol ratio (30 Participants per arm)

    Time frame: Day 0 and day 42

  13. To assess the efficacy of 6 weeks of daily consumption of two different mixes of HMO 2'-O-fucosyllactose (HMO-2FL) + Humiome® Post LB postbiotic (postbiotic-LB); on Stool pH & redox [to be conducted in 30 participants in each arm]

    Improved Stool pH (5.5 to 7.0) \& decreased redox potential of stool \[to be conducted in those participants who are undergoing LMR in each arm

    Time frame: Day 0 and day 42

Other outcomes

  1. To assess the efficacy of 6 weeks of daily consumption of two different mixes of HMO 2'-O-fucosyllactose (HMO-2FL) + Humiome® Post LB postbiotic (postbiotic-LB); on gut microbiome composition compared to baseline, each other and placebo

    Improved Microbiome composition (i.e., increased in beneficial bifidobacteria) (on a selection of samples) will be analyzed using full shotgun sequencing (Illumina Hiseq 150 x2). This will be done on selection of samples

    Time frame: day 0 and day 42

  2. To assess the efficacy of 6 weeks of daily consumption of two different mixes of HMO 2'-O-fucosyllactose (HMO-2FL) + Humiome® Post LB postbiotic (postbiotic-LB); on microbiome diversity compared to baseline, each other and placebo

    Improved microbiome diversity (alpha and beta) will be analyzed (on a selection of samples) using full shotgun sequencing (Illumina Hiseq 150 x2) This will be done on selection of samples

    Time frame: day 0 and day 42

  3. To assess the efficacy of 6 weeks of daily consumption of two different mixes of HMO 2'-O-fucosyllactose (HMO-2FL) + Humiome® Post LB postbiotic (postbiotic-LB); on fecal metabolomics profile compared to baseline, each other and placebo

    Other fecal metabolites will be analysed for improvement (on a selection of samples) by an untargeted metabolomics approach using (semi-polar LC-MS/MS method. This will be done on selection of samples

    Time frame: day 0 and day 42

  4. To assess the efficacy of 6 weeks of daily consumption of two different mixes of HMO 2'-O-fucosyllactose (HMO-2FL) + Humiome® Post LB postbiotic (postbiotic-LB); on Changes in organic acids in fecal samples compared to baseline, each other and placebo

    Improvement in fecal organic acids (acetate, propionate, butyrate, valerate, lactate) as analyzed (on a selection of samples) by a targeted quantitative SCFA method (GC-MS). This will be done on selection of samples

    Time frame: day 0 and day 42

07

Study locations

12 sites
  • Shri. B. M. PatilMedical College,Hospital andResearch Centre
    Vijayapura, Karnataka 586103, India
  • Shivam Hospital
    Dombivali, Maharashtra 421201, India
  • Aster Aadhar Hospital
    Kolhāpur, Maharashtra 416012, India
  • D Y Patil
    Navi Mumbai, Maharashtra 400706, India
  • Dhanwantari Hospital
    Pune, Maharashtra 411002, India
  • Silver Birch
    Pune, Maharashtra 411041, India
  • Vishwaraj hospital
    Pune, Maharashtra 412201, India
  • D Y Patil Hospital, Medical college and research centre
    Thane, Maharashtra 400706, India
  • Dr. Naresh Bansal's Gastro & Liver Clinic
    New Delhi, National Capital Territory of Delhi 110058, India
  • Jaipur National University Institute of Medical Sciences and Research Centre
    Jaipur, Rajasthan 302017, India
  • Samvedna Hospital
    New Colony, Ravindrapuri Varanasi 221005, India
  • Gleneagles Global Hospitals
    Hyderabad, Telangana 500004, India
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in Jun 2026, 14 months.

Of 52 industry-sponsored interventional studies with no phase under Irritable Bowel Syndrome, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 28. This study's 14 months is close to that.

Counting every sponsor, half of 360 studies reached it within 19 months; a quarter within 9 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2025
First posted
Mar 21, 2025
StartActual
Mar 27, 2025
Primary completionActual
Jun 6, 2026
CompletionActual
Jun 6, 2026
Last update
Jul 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06889779
Responsible party
Sponsor
First posted
Mar 21, 2025
Start date
Mar 27, 2025
Primary completion
Jun 6, 2026
Completion
Jun 6, 2026
Last update
Jul 22, 2026

Study contacts

Mehdi Sadaghian, PhD
study director · dsm-firmenich Switzerland AG

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion